Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's coming soon!
Anything is possible but be happy if it holds 20. Looking for a sell off going into a long weekend.
They have a short interest is my guess. And INO is am easy targert... easily manipulated with a high short interest ratio.
Truth! Once the pressure is finally on it's going to be a fun ride.
Looks like someone desperately needed beer money for the weekend
Interesting. I didn't see it come across. Sorry. Disappointing but the PPS will catch up. They should have waited until monday to release it.
They need to get the word out on a global news wire with an official PR.
SSR is effective today. As long as we maintain minimal buying pressure it should be a pretty easy day.
I wont miss it. Been here a long time. Patience is a blessing with this one.
Could also just be following general market trends. Waiting 20 min for jobs report to be released to see what happens.
Could be. Still watching and waiting. Historically speaking INO doesnt like days that start with an uptick in PM without news.
Bingo! Now it's just a matter of what range it decides to consolidate in.
Lawsuit is irrelevant at this point.
"Nucleic acids vaccines development, testing and production: DoD-Advance Development and Manufacturing (ADM) has transferred the manufacturing process from Inovo and initiated manufacturing and scale up for a promising DNA-plasmid based vaccine candidate. This technology is expected to provide DoD-based surge capability for vaccine production. The vaccine could be used in phase 2 context to protect DoD personnel, healthcare workers or others at risk for COVID-19 exposure."
It's all good. This was inevitable. The only thing that would have stopped this is news of more funding. This is the 4th time now. A couple of the others did the same thing up until they got the major funding. We should be settling out in that 14 to 16 range in the next trading day or two and establishing the next up. Just be on the look out for the next news. When it hits it will be game on. Chances are it is coming sooner than later.
Hopefully you have been setting up Remarks lol
Question: Eddie is talking about dividends but he spends most of his time focusing on Auri. In the event that this turn around actually happens would dividends just be paid out for Auri investors or for PBS also.
I'm hopeing it takes a quick bounce back down to that range also.. I'll take every one I can get my hands on.
I should see if they want to hire me as a commission only sales guy for AZ while I'm working from home lol
Yeah I live in AZ. This $hit is getting real fast. Already closing things down again.
Exactly but to truthfully answer that question the .20 difference is roughly 2k more profit to start. Hence why the wait. The party hast started yet for the major run so I'll take my chances. I've already accumulated a decent starter's kit in the event I end up missing out on more lows. So at this point I dont see the need to have to average up yet.
I'm here for the long run. I've already hit the ask a couple times the last few days. I'm just waiting for more.
It can go below .80 first though please. I want some cheaper cheapies.. lol
Referring back to my previous post from last night. Their is nothing wrong with the data that they submitted. The are taking the higher road of having it peer-reviewed before submitting to avoid potential litigation issues. The decrease in PPS decline sucks yes but will rebound in the very near future. Along with it will be another bout of analysis upgrades. It's the life cycle of a highly volatile stock.
INO-4800 P1 prelim pr:
Multiple immunology assays including those for humoral and cellular immune responses are being conducted for both 1.0 mg and 2.0 mg dose cohorts after two doses at week 6. Analyses to date have shown that 94% (34 out of 36 total trial participants) demonstrated overall immunological response rates based on preliminary data assessing humoral (binding and neutralizing) and T cell immune responses. One participant in the 1.0 mg dose cohort and two participants in the 2.0 mg dose cohort were excluded in the immune analyses as they tested positive for COVID-19 immune responses at study entry, indicating prior infection. One participant in the 2.0 mg dose cohort discontinued the study for reasons unrelated to safety or tolerability. INOVIO plans to publish the full data set in a peer-reviewed medical journal
INO-4700 P1 prelim pr:
The completed Phase 1 vaccine study INO-4700 was well tolerated and induced high levels of antibody responses in 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 used in that trial were maintained through 60 weeks following dosing.
NOTICE SOME SIMILARITIES... NOW FOR THE KICKER
INO-4700 peer reviewed results:
Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a neutralization assay (EMC2012-Vero neutralization). Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.
NOW YOU KNOW WHAT WE HAVE TO LOOK FOWARD TOO. ;)
I jumped to soon lol. But the same thing will happen here. Either ride it out or capitalize on the opportunity
But it did also go from 16.90 to 26 back to 16.50 then to 44 lol. Road that crazy train.
I jumped at 24 PM. Thank god. Now just waiting for the reload zone.
Agreed! Looking at reloading 16 to 17.
It's fine with me. Rinse wash and repeat. Just keep playing the spikes and ride the moving ang on up.
If it wacks 15 by close I'm going all in.
Oh I agree with that. And it wouldnt suprise me if they release the data to hedge against their own users.
Yeah I know I've been reading them. But I'm not going to bash on them to hard. They have made me some nice money the last couple months. Just wish they would hit a couple other I'm holding lol.
Cant say I blame them. It's easy prey. They are skittish little varmints
Oh I already have some just want more!!!
Someone sell off and drop this to .80 please. I want to load up lol.
If your concerned about the lack of info in todays press release look at this....
INO-4800 P1 prelim pr:
Multiple immunology assays including those for humoral and cellular immune responses are being conducted for both 1.0 mg and 2.0 mg dose cohorts after two doses at week 6. Analyses to date have shown that 94% (34 out of 36 total trial participants) demonstrated overall immunological response rates based on preliminary data assessing humoral (binding and neutralizing) and T cell immune responses. One participant in the 1.0 mg dose cohort and two participants in the 2.0 mg dose cohort were excluded in the immune analyses as they tested positive for COVID-19 immune responses at study entry, indicating prior infection. One participant in the 2.0 mg dose cohort discontinued the study for reasons unrelated to safety or tolerability. INOVIO plans to publish the full data set in a peer-reviewed medical journal
INO-4700 P1 prelim pr:
The completed Phase 1 vaccine study INO-4700 was well tolerated and induced high levels of antibody responses in 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 used in that trial were maintained through 60 weeks following dosing.
NOTICE SOME SIMILARITIES... NOW FOR THE KICKER
INO-4700 peer reviewed results:
Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a neutralization assay (EMC2012-Vero neutralization). Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.
NOW YOU KNOW WHAT WE HAVE TO LOOK FOWARD TOO. ;)
It sure has and still has a long ways to go. Future looks very promising.
Its INO would you expect anything less? We always have to take the hard rd lol
In this case I wish that they would have just waited until the results were reviews and released in its entirety. But the good news out of it is that they followed through with information regarding it prior to months end... for what it's worth.
They will be releasing the full results after they have been reviewed by peers. After the lawsuit a few months ago they are taking the cautious rd. Which I am more than fine with it increases the credibility moving foward.
Was a perfect sell the news situation. The results were better than expected. Take a look at new/old write up.